Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.78 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.78 |
| ▸ | FLT3 | P36888 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354248 | 1.00 | MEN1 (1.00) | MEN1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL6395923 | 0.91 | HDAC6 (0.84) | MEN1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL6389792 | 0.90 | MEN1 (0.82) | MEN1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL6866887 | 0.88 | PDGFRB (1.00) | MEN1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL6420769 | 0.87 | FLT3 (0.80) | MEN1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL6865103 | 0.87 | FLT3 (1.00) | MEN1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL6171445 | 0.87 | MEN1 (0.76) | MEN1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL5507174 | 0.86 | FLT3 (0.80) | MEN1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL6389802 | 0.86 | FLT3 (0.80) | MEN1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL7066254 | 0.86 | FLT3 (0.80) | MEN1CYP1A2CYP3A4CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20090042820-A1 | Tubulin Binding Anti Cancer Agents And Prodrugs Thereof | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-7094798-B1 | Inhibitors of checkpoint kinases (Wee1 and Chk1) | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20050267303-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | ZENTARIS AG | 2005-12-01 | — | — | US | disclosed |
| EP-1501831-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1423393-A1 | CYCLIC INDOLE AND HETEROINDOLE DERIVATIVES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Zentaris GmbH (DE) | 2004-06-02 | — | — | EP | disclosed |
| US-20040039197-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | WATERWORKS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003091255-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003020731-A1 | CYCLIC INDOLE AND HETEROINDOLE DERIVATIVES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | ZENTARIS GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042820-A1 | Tubulin Binding Anti Cancer Agents And Prodrugs Thereof | TUBB1, TUBB, TUBB6 | MEN1 4159/4885CYP1A2 4175/4885CYP3A4 4202/4885 |
| US-20050267303-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | IDO1, IDO2, INMT | MEN1 279/4885CYP1A2 99/4885CYP3A4 80/4885 |
| US-20040039197-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | IDO1, IDO2, INMT | MEN1 238/4885CYP1A2 96/4885CYP3A4 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.